Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BAY2701250 IV
BAY2701250 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| i.v. infusion cohorts | EXPERIMENTAL | Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of short time i.v. infusion. Up to 8 dose steps are planned to be investigated for i.v. administration. |
| s.c. injection cohorts | EXPERIMENTAL | Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of s.c. injection. Up to 2 dose steps are planned to be investigated for s.c. administration. |
| Name | Type | Description |
|---|---|---|
| BAY2701250 IV | DRUG | Single does, intravenous infusion |
| Placebo IV | DRUG | Matching placebo for BAY2701250 IV |
| BAY2701250 SC | DRUG | Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue |
| Placebo SC | DRUG | Matching placebo for BAY2701250 SC |
Inclusion Criteria: * Male, white participants aged 18 to 45 years * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, ECG and vital signs * Body weight ≥ 70 kg and ≤ 100 kg as well as body mass index (BMI) wi...
BAY2701250 is an investigational small molecule being developed by Bayer AG for pulmonary hypertension due to left heart disease, a cardiovascular condition. It is in Phase 1 clinical development and has been studied in healthy male volunteers. It is not an approved therapy.
BAY2701250 is being studied for pulmonary hypertension due to left heart disease. The only completed trial enrolled healthy male participants rather than patients with the condition, so the program remains at an early research stage and no approved use exists for BAY2701250.
BAY2701250 is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the Phase 1 study of the compound conducted in Germany.
BAY2701250 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA or any other regulator for any indication.
BAY2701250 has been evaluated in one completed Phase 1 trial, NCT06048120. That study enrolled 82 healthy male participants aged 18 and older in Germany and compared single intravenous infusion and subcutaneous injection doses in a controlled, randomized design. No trials are currently active.
Yes. BAY2701250 IV is an alternative name for BAY2701250, reflecting the intravenous infusion route tested in its Phase 1 study. The same compound was also given as a subcutaneous injection in that trial, which enrolled 82 healthy male volunteers.